Clinical Trials on Labour;Obstructed in Japan

Total 11 results

GlaxoSmithKline
PPD

Completed

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies (ARIOS)

Obstetric Labour, Premature

Germany, Israel, Italy, Korea, Republic of, Mexico, Spain, Belgium, United Kingdom, Sweden, United States, Japan
GlaxoSmithKline
PPD

Terminated

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor (NEWBORN-1)

Obstetric Labour, Premature

United States, Italy, United Kingdom, Japan, Canada
Bayer

Recruiting

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Retinopathy of Prematurity | Newborns | Infants

Japan
Kyushu University

Completed

PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity

Retinopathy of Prematurity

Japan
Nobelpharma

Completed

Clinical Study of Caffeine for Apnea of Prematurity

Apnea of Prematurity

Japan
The University of Texas Health Science Center,...
University of Alabama at Birmingham; University of Iowa; Nationwide Children's... and other collaborators

Recruiting

Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum Dataset

Premature Birth | Obstetric Labor, Premature | Infant, Extremely Premature | Intensive Care Units, Neonatal | Intensive Care, Neonatal

United States, Japan, Sweden
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy (FIREFLEYE)

Retinopathy of Prematurity (ROP)

Spain, Singapore, Hong Kong, Korea, Republic of, Malaysia, Japan, Taiwan, Sweden, Portugal, Belgium, Argentina, Bulgaria, Italy, Austria, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Poland, Romania, Russian Federation, Slov... and more
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (FIREFLEYE next)

Retinopathy of Prematurity (ROP)

Spain, Korea, Republic of, Singapore, Malaysia, Japan, Taiwan, Bulgaria, Italy, Argentina, Czechia, Greece, Israel, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Sweden, Turkey, United Kingdom, Ukraine, Hungary, Belgium and more
Novartis Pharmaceuticals

Completed

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (RAINBOW)

Retinopathy of Prematurity

United States, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, Estonia, France, Germany, Greece, Hungary, India, Italy, Japan, Lithuania, Malaysia, Mexico, Poland, Romania, Russian Federation, Saudi Arabia, Slovakia, Taiwan, Turkey, United...
Novartis Pharmaceuticals

Completed

Rainbow Extension Study (RainbowExt)

Retinopathy of Prematurity (ROP)

United States, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Romania, Russian Federation, Saudi Arabia, Slovakia, Taiwan, Turkey, United Kingdom, Lithuania, Estonia
OHB Neonatology Ltd.

Recruiting

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

Intraventricular Hemorrhage | Bronchopulmonary Dysplasia | Chronic Lung Disease of Prematurity | Retinopathy of Prematurity (ROP)

Finland, United States, France, Italy, United Kingdom, Germany, Canada, Ireland, Japan, Netherlands, Portugal, Spain, Sweden

Clinical Trials on Labour;Obstructed in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations